It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Aims
This study aimed to determine whether any change occurred over time in level of evidence (LoE) of therapeutic interventions supporting heart failure (HF) and other European Society of Cardiology guideline recommendations.
Methods and results
We selected topics with at least three documents released between 2008 and April 2022. Classes of recommendations (CoR) and supporting LoE related to therapeutic interventions within each document were collected and compared over time. A total of 1822 recommendations from 18 documents on 6 topics [median number per document = 112, 867 (48%) CoR I] were included in the analysis. There was a trend towards a reduction over time in the percentage of CoR I in HF (46–36–34%), non‐ST elevation myocardial infarction (NSTEMI; 78–58–54%), and pulmonary embolism (PE; 65–50–39%) guidelines, with a decrease in the total number of recommendations for HF only. Percentage of CoR I was stable over time around 40% for valvular heart disease (VHD) and atrial fibrillation (AF), and around 60% for cardiovascular prevention (CVP), with an increase in the total number of recommendations for VHD and CVP and a decrease for AF. Among CoR I, 319 (37%) were supported by LoE A, with a decrease over time for HF (56–46–42%), an increase for NSTEMI (29–38–48%) and AF (28–31–36%), a bimodal distribution for PE and CVP, and a lack for VHD.
Conclusions
LoE supporting therapeutic recommendations in contemporary European guidelines is generally low. Physicians should be aware of these limitations, and scientific societies promote a greater understanding of their significance and drive future research directions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; De Marzo, Vincenzo 2 ; Ameri, Pietro 1 ; Ferrari, Roberto 3 ; Tavazzi, Luigi 4 ; Rapezzi, Claudio 5 ; Porto, Italo 1 ; Maggioni, Aldo Pietro 6 1 Cardiology Unit, Ospedale Policlinico San Martino IRCCS, Genoa, Italy, Department of Internal Medicine, University of Genova, Genoa, Italy
2 Department of Internal Medicine, University of Genova, Genoa, Italy
3 Scientific Department, MTA Group, Lugano, Switzerland, Azienda Ospedaliero‐Universitaria di Ferrara ‘Arcispedale S. Anna’, Ferrara, Italy
4 Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy
5 Azienda Ospedaliero‐Universitaria di Ferrara ‘Arcispedale S. Anna’, Ferrara, Italy, Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy
6 Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy, Centro Studi ANMCO, Heart Care Foundation, Florence, Italy





